JP2012512157A5 - - Google Patents

Download PDF

Info

Publication number
JP2012512157A5
JP2012512157A5 JP2011540796A JP2011540796A JP2012512157A5 JP 2012512157 A5 JP2012512157 A5 JP 2012512157A5 JP 2011540796 A JP2011540796 A JP 2011540796A JP 2011540796 A JP2011540796 A JP 2011540796A JP 2012512157 A5 JP2012512157 A5 JP 2012512157A5
Authority
JP
Japan
Prior art keywords
cancer
medicament
class
selective hdac
enzastaurine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2011540796A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012512157A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2009/066925 external-priority patent/WO2010074936A2/en
Publication of JP2012512157A publication Critical patent/JP2012512157A/ja
Publication of JP2012512157A5 publication Critical patent/JP2012512157A5/ja
Withdrawn legal-status Critical Current

Links

JP2011540796A 2008-12-15 2009-12-07 癌を治療するためのエンザスタウリン Withdrawn JP2012512157A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12245108P 2008-12-15 2008-12-15
US61/122,451 2008-12-15
PCT/US2009/066925 WO2010074936A2 (en) 2008-12-15 2009-12-07 Enzastaurin for the treatment of cancer

Publications (2)

Publication Number Publication Date
JP2012512157A JP2012512157A (ja) 2012-05-31
JP2012512157A5 true JP2012512157A5 (cg-RX-API-DMAC10.html) 2012-08-23

Family

ID=41785627

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011540796A Withdrawn JP2012512157A (ja) 2008-12-15 2009-12-07 癌を治療するためのエンザスタウリン

Country Status (11)

Country Link
US (1) US20110288032A1 (cg-RX-API-DMAC10.html)
EP (1) EP2376081A2 (cg-RX-API-DMAC10.html)
JP (1) JP2012512157A (cg-RX-API-DMAC10.html)
KR (1) KR20110084533A (cg-RX-API-DMAC10.html)
CN (1) CN102245184A (cg-RX-API-DMAC10.html)
AU (1) AU2009330492A1 (cg-RX-API-DMAC10.html)
BR (1) BRPI0922367A2 (cg-RX-API-DMAC10.html)
CA (1) CA2746085A1 (cg-RX-API-DMAC10.html)
EA (1) EA201170821A1 (cg-RX-API-DMAC10.html)
MX (1) MX2011006433A (cg-RX-API-DMAC10.html)
WO (1) WO2010074936A2 (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX380504B (es) 2010-06-03 2025-03-12 Pharmacyclics Llc El uso de inhibidores de la tirosina quinasa de bruton (btk).
WO2013112598A1 (en) * 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Method of treatment of nasopharyngeal caner
WO2013112601A1 (en) * 2012-01-24 2013-08-01 Millennium Pharmaceuticals, Inc. Methods of treatment of cancer
EP2814493A4 (en) * 2012-02-17 2015-07-22 Pharmacyclics Inc COMBINATIONS OF HISTONE DEACETYLASE INHIBITOR AND PAZOPANIB, AND USES THEREOF
HK1206073A1 (en) 2012-07-24 2015-12-31 药品循环有限责任公司 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
AU2014290012B2 (en) * 2013-07-19 2020-01-16 Onyx Therapeutics, Inc. Peptide epoxyketone proteasome inhibitors in combination with PIM kinase inhibitors for treatment of cancers
US9885086B2 (en) 2014-03-20 2018-02-06 Pharmacyclics Llc Phospholipase C gamma 2 and resistance associated mutations
WO2017011314A1 (en) * 2015-07-10 2017-01-19 Paharmacyclics Llc Btk and hdac combinations
WO2020223657A1 (en) * 2019-05-02 2020-11-05 Predictive Technology Group, Inc. Somatic cancer driver mutations in endometriosis lesions contribute to secondary cancer risk

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1449529B1 (en) 1993-12-23 2010-01-27 Eli Lilly And Company Protein Kinase C Inhibitors
US20080096923A1 (en) * 2004-07-23 2008-04-24 Aniz Girach Methods For Diagnosing And Treating Diabetic Microvascular Complications
US20090202659A1 (en) * 2005-06-10 2009-08-13 Gimble Jeffrey M Modulation of Peripheral Clocks in Adipose Tissue

Similar Documents

Publication Publication Date Title
Mitchell Gastrointestinal toxicity of chemotherapeutic agents
CY1112320T1 (el) Τιτλοδοτηση της ταπενταδολης
NZ599464A (en) Combination therapies using hdac inhibitors
EA201300323A1 (ru) Материалы и способы улучшения функции желудочно-кишечного тракта
EP3738587A3 (en) Dosage form for insertion into the mouth
EA200900155A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
MX2009003372A (es) Formas de dosificacion de pelicula no mucoadhesiva.
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
DE602007007991D1 (de) Kleinvolumige, orale, transmukosale dosierungsformen mit sufentanil zur schmerzbehandlung
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
WO2012117257A8 (en) Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer
EA201100153A1 (ru) Никотинсодержащие мягкие желатиновые пастилки
EA201000855A1 (ru) Способ и средства для достижения бронхиальной релаксации
WO2009004995A1 (ja) 生理活性物質を定着および発現させる方法
CU20110170A7 (es) Combinaciones farmacéuticas que comprenden rdea119/bay 869766 para el tratamiento de cánceres específicos
CY1117568T1 (el) Χρηση μιας συνθεσης η οποια περιλαμβανει φορμοτερολη και διπροπιονικη βεκλομεθαζονη για την αγωγη μιας εξαρσης ασθματος
EA201170821A1 (ru) Энзастаурин для лечения рака
ATE543492T1 (de) Behandlung von lungenkrebs
MX2010004350A (es) Metodos de uso del acido (+)-1,4-dihidro-7-[(3s,4s)]-3-metoxi-4-(m etilamino)-1-pirrolidinil-4-oxo-1-(2-tiazolil)-1, 8-naftiridina-3-carboxilico en terapias de combinacion.
UA113841C2 (xx) Сірководневі похідні нестероїдних протизапальних лікарських засобів
EA201390417A1 (ru) Антидиабетические твердые фармацевтические композиции
TN2010000266A1 (en) Oxazolidinones for the treatment and/or prophylaxis of heart failure
MX2009009230A (es) Uso de silodosina en una administracion diaria para tratar hiperplasia prostatica benigna.
NZ604009A (en) A combination composition comprising ibuprofen and paracetamol
MX2009008813A (es) Composicion farmaceutica que contiene floroglucinol y paracetamol.